TFA Therapeutics, Inc. (RAJAF) stock
RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$9.18+0.00 (0.00%)
Close on Oct 16, 2026Market cap –P/E –Yield –
TFA Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
TFA Therapeutics's operating income for the twelve months ending Dec 31, 2023 was $227.83K. For fiscal 2025 it was -$141.13K. The highest annual figure on record is $227.83K in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$141.13K | – |
| FY2024 | Dec 31, 2024 | -$183.91K | -180.7% |
| FY2023 | Dec 31, 2023 | $227.83K | – |
| FY2022 | Dec 31, 2022 | -$415.12K | – |
| FY2021 | Dec 31, 2021 | -$119.39K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $120.45K | – |
| Q4 FY2022 | Dec 31, 2022 | -$36.90K | – |
See a number that looks wrong?